Every 10-Q that Teleflex Incorporated (TFX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TFX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TFX filings page.
Teleflex Incorporated reported strong top-line growth but weaker profitability for the quarter ended June 30, 2026. Net revenues from continuing operations were $570.3 million, up 28.9% from $442.5 million, driven largely by $99.0 million of sales from the acquired BIOTRONIK Vascular Intervention business and higher volumes of existing products.
Gross margin declined to 58.2% from 60.1% as tariffs enacted in 2025, the lower-margin profile of the VI Business, and related intangible amortization pressured costs. Income from continuing operations was $41.8 million versus $68.2 million a year earlier, while net income, including discontinued operations, was $99.7 million compared with $122.6 million.
Teleflex is executing a major portfolio reshaping through “Strategic Divestitures” of its OEM, Acute Care and Interventional Urology businesses for a combined $2.0 billion in cash. On August 3, 2026, it completed the OEM sale, receiving $1.5 billion of net proceeds and expects an approximately $1.0 billion pre-tax gain, using part of the cash to repay the $700 million term A-2 loan facility.
Teleflex grew first-quarter 2026 net revenues to $548.3 million, up 32.3% from a year earlier, driven mainly by the acquired BIOTRONIK Vascular Intervention business and higher volumes of existing products. Despite this growth, gross margin fell to 56.1% from 61.7% due to 2025 tariffs, acquisition-related amortization, quality and inventory costs, and higher logistics expenses.
The company reported a net loss of $8.2 million, compared with net income of $95.0 million a year ago, as selling, general and administrative and research and development expenses rose with the VI Business, restructuring programs and CEO severance. Discontinued operations tied to planned divestitures of the Acute Care, Interventional Urology and OEM businesses also shifted from a $42.7 million profit to a $3.3 million loss, including a $29.0 million valuation allowance. Teleflex expects $2.0 billion in cash proceeds from these sales and plans to use about $1.8 billion of net after-tax proceeds mainly for share repurchases and debt reduction.
Teleflex (TFX) reported a sharp swing to loss on non-cash charges. For the quarter ended September 28, 2025, net revenues were $913,021, up from $764,375 a year ago, reflecting contributions from the newly acquired Vascular Intervention business. However, the company posted a net loss of $(408,892), driven primarily by a $403,925 goodwill impairment in Interventional Urology and a $100,000 impairment tied to Titan SGS.
Operating trends were mixed: gross profit rose to $451,642, but higher SG&A and R&D, plus restructuring and separation costs, pressured results. Year‑to‑date, revenue reached $2,394,579 while net loss was $(191,310). Teleflex closed the BIOTRONIK Vascular Intervention acquisition for €704.3 million ($825.2 million) and financed it with a $700 million delayed draw term loan and additional revolver borrowings. Total borrowings increased to $2,681,250, and cash from operations was $188,971 year‑to‑date as investing cash outflows reflected the acquisition.
The company is advancing plans to separate NewCo, with $32,144 in year‑to‑date separation costs. Shares outstanding were 44,194,408 as of November 4, 2025.